Assisted reproductive technology represents one of the most transformative frontiers in modern medicine, fundamentally reshaping human reproduction, family building, and clinical embryology. By intervening at the very earliest stages of cellular life, these biomedical innovations provide viable solutions to reproductive failure while challenging classical ontological, bioethical, and socio-legal frameworks.
Assisted Reproductive Technology (ART)
1. Concise Definition
Assisted reproductive technology (ART) encompasses all clinical interventions, laboratory procedures, and biomedical manipulations that involve the in vitro handling of both human oocytes and sperm, or embryos, for the purpose of establishing a pregnancy. According to standardized international medical definitions, ART strictly excludes procedures in which only sperm are handled (such as intrauterine insemination) or procedures where women take medication solely to stimulate oocyte production without subsequent laboratory gamete retrieval.
In operational clinical practice, ART functions as a comprehensive continuum of multidisciplinary care. It synthesizes controlled ovarian hyperstimulation, ultrasound-guided transvaginal oocyte aspiration, gamete cryopreservation, in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and embryo culture and transfer. ART serves as both a therapeutic modality for biological infertility and a proactive mechanism for fertility preservation, single-parent reproduction, and gestational surrogacy for diverse family constellations.
2. Etymology & Linguistic Origin
The term assisted reproductive technology is an English compound phrase constructed during the rapid expansion of reproductive endocrinology throughout the late 1970s and 1980s. The constituent term assisted derives from the Middle French assister and the Latin assistere (meaning “to stand by, aid, or help”, formed from ad- [“to”] and sistere [“to cause to stand”]). The term reproductive traces back through French to the Classical Latin reproducere (composed of re- [“again”] and producere [“to bring forth, lead forward, or generate”]). The noun technology originates from the Greek technologia (τεχνολογία), a systematic treatment of an art, craft, or technique, combining techne (τίχνη, meaning “art, craft, skill, or practical method”) and logos (λόγος, meaning “discourse, reason, or branch of study”).
Historically, early medical literature referred to the broader discipline using colloquial or narrow clinical expressions, most notably “test-tube baby technology” or simple “in vitro fertilization.” As the field expanded to encompass micromanipulation, cryopreservation, and gamete donation, the broader umbrella acronym ART was codified by epidemiological surveillance bodies, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), to establish clear ontological and clinical boundaries within reproductive surveillance systems.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed in the International Phonetic Alphabet (IPA) as /⊂ˈsɪstɪd ˌriːprəˈdʌktɪv tɛkˈnɒlədʒi/ in British English and /əˈsɪstɪd ˌriprəˈdʌktɪv tɛkˈnɑːlədʒi/ in American English. The acronym ART is universally pronounced either as the lexical monosyllable /ɑːt/ (UK) or /ɑːrt/ (US), or enunciated initialistically as individual letters: /eɪ-ɑːr-tiː/.
Grammatical Form: Compound noun phrase, primarily functioning as a non-count (uncountable) mass noun when referring to the medical field, paradigm, or aggregate domain (e.g., “advances in assisted reproductive technology”). It regularly operates as a countable noun in its plural form—assisted reproductive technologies (ARTs)—when delineating distinct biomedical techniques, protocols, or platforms. In medical syntax, the acronym ART is frequently employed as an attributive noun or nominal modifier (e.g., “ART cycle,” “ART pregnancy,” “ART outcomes”).
4. Detailed Conceptual Explanation
Assisted reproductive technology occupies a distinct, highly regulated domain within reproductive biomedicine and clinical endocrinology. To fully delineate its scope, clinical guidelines established by surveillance authorities, such as the International Committee for Monitoring Assisted Reproductive Technologies (ICMART), distinguish ART from broader fertility treatments. Standard medical management of infertility encompasses lifestyle modifications, medical ovulation induction using oral antiestrogens (such as clomiphene citrate) or aromatase inhibitors (such as letrozole), and intrauterine insemination (IUI). However, an intervention only crosses the definitive conceptual threshold into ART when human oocytes are surgically or clinically extracted from the ovaries and manipulated extracorporeally alongside spermatozoa within a laboratory setting.
The conceptual framework of an ART cycle spans several physiological and biomedical stages. It typically initiates with pituitary down-regulation or gonadotropin-releasing hormone (GnRH) suppression, followed by controlled ovarian stimulation using exogenous gonadotropins (follicle-stimulating hormone, luteinizing hormone) to recruit a cohort of multiple mature follicles. The physiological process culminates in the pharmacological administration of human chorionic gonadotropin (hCG) or a GnRH agonist to trigger final oocyte maturation. Following ultrasound-guided transvaginal oocyte retrieval, clinical embryologists orchestrate the in vitro microenvironment—meticulously regulating pH, temperature, gas mixture (low oxygen tension), osmolality, and essential amino acids—to facilitate gamete interaction, fertilization, embryonic cleavage, and extended blastocyst culture.
Beyond conventional IVF, contemporary ART incorporates advanced bioengineering and micromanipulation paradigms. The development of intracytoplasmic sperm injection directly bypasses natural sperm-zona pellucida binding barriers to treat severe male-factor subfertility. Concurrently, ultrarapid cryopreservation (vitrification) has eliminated traditional ice-crystal damage, making elective and oncological gamete/embryo banking clinically reliable. Modern ART also integrates preimplantation genetic testing (PGT-A for aneuploidies, PGT-M for monogenic disorders, and PGT-SR for structural rearrangements), shifting the discipline from an empirical effort to induce conception toward a precision reproductive genomic science.
The boundaries of ART are dynamic and subject to ongoing bioethical clarification. Novel experimental paradigms—such as in vitro gametogenesis (IVG) derived from induced pluripotent stem cells (iPSCs), artificial uterine incubation (ectogenesis), mitochondrial replacement therapy (MRT), and somatic cell nuclear transfer—continue to push the biological limits of reproduction. Consequently, ART represents an interdisciplinary nexus connecting molecular biology, reproductive physiology, bioinformatics, bioethics, and medical jurisprudence.
5. Historical Development
The historical trajectory of assisted reproductive technology transitioned from mid-twentieth-century mammalian animal experimentation to human clinical breakthroughs. Foundational physiological research on mammalian fertilization by Min Chueh Chang in the 1950s laid the essential groundwork for maintaining gamete viability and capacitation in laboratory vessels. The defining milestone in human medicine occurred on July 25, 1978, in Oldham, United Kingdom, with the birth of Louise Joy Brown. This historic achievement was the culmination of collaborative research between reproductive physiologist Robert G. Edwards and gynecologic surgeon Patrick Steptoe, alongside embryologist Jean Purdy. Edwards was subsequently awarded the 2010 Nobel Prize in Physiology or Medicine for the development of human in vitro fertilization.
Throughout the early 1980s, IVF clinics emerged globally, marked by the birth of Candice Reed in Australia (1980) and Elizabeth Carr in the United States (1981). However, early cycles relied heavily on natural menstrual cycles, resulting in high cancellation rates and low implantation probabilities. The systematic introduction of controlled ovarian stimulation using urinary and later recombinant gonadotropins substantially increased oocyte yields and cycle efficiency. Cryopreservation protocols advanced rapidly, marked by the first successful pregnancy from a frozen-thawed human embryo reported by Alan Trounson and colleagues in Melbourne in 1983.
In 1992, Gianpiero Palermo and colleagues in Brussels introduced intracytoplasmic sperm injection (ICSI), completely transforming the management of severe male-factor infertility. The 1990s and 2000s witnessed the development of blastocyst-stage culture (extending embryonic development to day 5 or 6), which improved embryo-endometrial synchrony and allowed the widespread clinical adoption of elective single embryo transfer (eSET). In parallel, the transition from slow-programmable freezing to vitrification drastically improved post-thaw survival rates for delicate unfertilized human oocytes. Contemporary milestones center on high-throughput next-generation sequencing (NGS) platforms for preimplantation genetic screening and the integration of artificial intelligence algorithms for time-lapse morphokinetic embryo selection.
6. Theoretical Foundations
Assisted reproductive technology is underpinned by a synthesis of classic endocrinological feedback theory, molecular embryology, and evolutionary reproductive biology. At the physiological core is the hypothalamic-pituitary-gonadal (HPG) axis model. In natural fecundity, negative feedback loops driven by estradiol and inhibin regulate pituitary follicle-stimulating hormone (FSH) secretion, resulting in the physiological selection of a single dominant Graafian follicle while subordinate follicles undergo atresia. ART theory exploits the plasticity of this system: by administering supraphysiological doses of exogenous gonadotropins, clinicians pharmacologically override the natural selection threshold, rescuing the entire cohort of developing antral follicles from apoptotic pathways.
A second conceptual foundation is the microenvironmental niche and epigenetic programming hypothesis. This biological principle recognizes that preimplantation mammalian embryos undergo extensive chromatin remodeling, parent-specific genomic imprinting, and early lineage specification (separating the inner cell mass from the trophectoderm). ART laboratory theory holds that in vitro culture conditions must emulate the dynamic physiological milieu of the human Fallopian tube and uterine cavity. Any microenvironmental disequilibrium—such as oxidative stress, heavy metal contamination, or suboptimal nutrient gradients—can induce cellular stress responses, alter metabolic fluxes, and perturb genomic imprinting.
From a sociological and psychoanalytic perspective, ART intersects with stratified reproduction theory, formulated by anthropologist Shellee Colen, and biopolitical theory, derived from Michel Foucault. These social science frameworks analyze how biological reproduction is culturally validated, commodified, and medically mediated. They interrogate how access to assisted conception is structured across axes of socioeconomic status, race, geographic location, and legal standing, elucidating how technological interventions redefine parenthood, genetic kinship, and human bodily autonomy.
7. Key Components, Types & Dimensions
Assisted reproductive technology comprises an integrated ecosystem of distinct laboratory, clinical, and diagnostic methodologies:
- In Vitro Fertilization (IVF): The foundational ART technique in which retrieved oocytes and capacitated spermatozoa are co-incubated in specialized culture medium inside an incubator, allowing fertilization to occur via natural sperm penetration through the cumulus-oocyte complex and zona pellucida.
- Intracytoplasmic Sperm Injection (ICSI): An advanced micromanipulation technique whereby a single immobilized, morphologically normal spermatozoon is directly injected into the ooplasm of a mature metaphase II oocyte using an ultra-fine glass micropipette, bypassing severe oligospermia, asthenozoospermia, or previous fertilization failure.
- Preimplantation Genetic Testing (PGT): The genetic analysis of biopsied embryonic cells (typically 5 to 10 trophectoderm cells extracted at the blastocyst stage) prior to transfer. Subtypes include:
- PGT-A: Screening for numerical chromosome abnormalities (aneuploidies).
- PGT-M: Targeted diagnostic testing for specific single-gene mutations (monogenic disorders such as cystic fibrosis, Huntington’s disease, or sickle cell anemia).
- PGT-SR: Detection of unbalanced structural chromosomal rearrangements (translocations, inversions).
- Gamet and Embryo Cryopreservation (Vitrification): An ultra-rapid cooling procedure using high concentrations of cryoprotectants that solidifies liquids into an amorphous, glass-like state without damaging intracellular ice crystal formation, enabling long-term storage of oocytes, sperm, and blastocysts.
- Third-Party Assisted Reproduction: Modalities involving external biological or gestational contributions:
- Oocyte, Sperm, or Embryo Donation: Utilization of donor gametes or surplus embryos when patient-derived reproductive material is absent or genetically compromised.
- Gestational Surrogacy: An arrangement where a gestational carrier agrees to carry a pregnancy created via ART using gametes from intended parents and/or donors, without genetic contribution from the carrier.
- Ovarian and Testicular Tissue Cryopreservation: Surgical harvesting and freezing of gonadal tissue strips before gonadotoxic chemotherapy, radiotherapy, or surgical castration, with subsequent autotransplantation to restore endocrine and gametogenic function.
8. Examples & Illustrative Cases
Case Illustration 1: Severe Male-Factor and Tubal Infertility
A 32-year-old female and a 35-year-old male present with five years of primary infertility. Hysterosalpingography reveals bilateral tubal occlusion secondary to past pelvic inflammatory disease, rendering natural conception physiologically impossible. Concurrently, semen analysis demonstrates severe oligoasthenoteratozoospermia (sperm concentration <2 million/mL, 10% progressive motility, 1% normal morphology). The couple is indicated for ART incorporating controlled ovarian stimulation, ultrasound-guided oocyte retrieval, and ICSI. Ten mature oocytes are retrieved; eight undergo successful fertilization via ICSI. Following extended culture, three high-quality blastocysts develop. A single vitrified-warmed blastocyst is transferred in a subsequent natural cycle, resulting in an intrauterine singleton pregnancy and term delivery.
Case Illustration 2: Autosomal Dominant Disease Prevention via PGT-M
A 29-year-old woman carries the autosomal dominant Huntington’s disease (HTT) gene expansion mutation and wishes to avoid transmitting the neurodegenerative condition to her offspring. The couple elects to undergo an ART cycle with PGT-M and PGT-A. Following ovarian hyperstimulation and IVF with ICSI, fourteen blastocysts are biopsied. Molecular analysis using targeted next-generation sequencing identifies six embryos free of the pathological CAG repeat expansion and verified as euploid. One unaffected blastocyst is transferred, leading to a successful pregnancy devoid of the familial genetic defect, while the remaining unaffected blastocysts remain cryopreserved for future family building.
Case Illustration 3: Oncofertility Gamete Banking Prior to Chemotherapy
A 24-year-old nulliparous woman is diagnosed with stage II Hodgkin lymphoma, requiring urgent gonadotoxic multi-agent chemotherapy with alkylating agents. Recognizing the substantial risk of premature ovarian insufficiency, her oncology team coordinates a rapid-start random-cycle ovarian stimulation protocol via a dedicated oncofertility service. Twelve mature oocytes are successfully collected and vitrified within a two-week window prior to her first chemotherapy infusion, preserving her future reproductive capacity.
9. Measurement & Assessment
The monitoring, clinical assessment, and outcome measurement of ART involve rigorous laboratory metrics, physiological biomarkers, and standardized epidemiological ratios defined by international reporting networks:
During the clinical phase, ovarian reserve and stimulation response are quantified using serial serum antimullerian hormone (AMH) concentrations, baseline antral follicle counts (AFC) via high-resolution transvaginal ultrasonography, and dynamic serum estradiol measurements. Embryological assessment utilizes standardized scoring rubrics, such as the Gardner grading system for blastocysts, which categorizes embryos based on degree of expansion (grades 1–6), cellular integrity of the inner cell mass (grades A, B, C), and trophectoderm cohesion (grades A, B, C). Continuous time-lapse imaging (TLI) systems apply artificial intelligence and morphokinetic algorithms—such as timing of cleavage divisions (t2, t3, t4) and blastulation initiation (tB)—to objectively predict implantation potential without disturbing incubator culture conditions.
Epidemiological and clinical success is measured across several standardized performance indicators:
- Fertilization Rate: The percentage of oocytes displaying two distinct pronuclei (2PN) 16 to 18 hours post-insemination or ICSI.
- Implantation Rate: The number of gestational sacs observed on transvaginal ultrasound divided by the total number of embryos transferred.
- Clinical Pregnancy Rate (CPR): The presence of at least one intrauterine gestational sac exhibiting fetal cardiac activity per started cycle, retrieval, or embryo transfer.
- Live Birth Rate (LBR): The primary clinical endpoint, defined as the delivery of one or more living infants surviving past 22 completed weeks of gestation, calculated per cycle started or per embryo transfer procedure.
- Cumulative Live Birth Rate (CLBR): The aggregate probability of a live birth resulting from one initiated ART cycle, encompassing all fresh and vitrified-thawed embryo transfers derived from that single oocyte aspiration cohort.
10. Applications & Practical Significance
Assisted reproductive technology has evolved far beyond its original mandate as a mechanical bypass for irreparable tubal disease. In clinical medicine, ART serves as the definitive therapy for long-standing idiopathic infertility, advanced maternal age, severe male factor infertility, severe endometriosis, and chronic anovulation refractory to medical induction. Furthermore, the field of oncofertility leverages ART to preserve reproductive potential in pediatric and adult cancer patients undergoing gonadotoxic therapies, hematopoietic stem cell transplants, or ovarian resection.
In human genetics and preventive medicine, ART provides a reliable alternative to prenatal amniocentesis and chorionic villus sampling through PGT. Prospective parents carrying balanced structural chromosomal rearrangements, sex-linked hereditary conditions, or severe autosomal dominant/recessive disorders can selectively establish pregnancies unaffected by familial diseases, minimizing difficult decisions surrounding late-stage termination of pregnancy.
Socially and demographically, ART serves as a primary facilitator of family building for single parents by choice and LGBTQ+ individuals and couples. Through gestational surrogacy, donor insemination, and reciprocal IVF (where one partner provides the oocytes and the other carries the pregnancy), ART dismantles biological constraints, expanding the architecture of the modern family. On a macroeconomic scale, as birth rates fall below replacement thresholds across industrialized nations, ART subsidizes national demographic replenishment, contributing to an estimated aggregate of over 10 million individuals born via these technologies worldwide.
11. Research & Empirical Evidence
The academic literature on assisted reproductive technology is vast, characterized by large-scale randomized controlled trials (RCTs), prospective cohort studies, and international registry analyses conducted by bodies such as the CDC’s Division of Reproductive Health, the European Society of Human Reproduction and Embryology (ESHRE), and the International Committee for Monitoring Assisted Reproductive Technologies (ICMART).
A major focus of clinical research has been the reduction of iatrogenic multiple gestations. Seminal clinical trials, such as the multi-center Finnish studies led by Hannu Martikainen and colleagues, demonstrated that elective single embryo transfer (eSET) combined with modern vitrification protocols achieves cumulative live birth rates comparable to double embryo transfer (DET) while virtually eliminating the maternal, fetal, and neonatal risks associated with multiple gestations (preterm birth, low birth weight, and cerebral palsy). Consequently, national registries show a clear shift toward eSET as the global standard of care.
Another primary research domain addresses safety and long-term perinatal outcomes. Large-scale population health analyses from Scandinavian registries (e.g., Ulla-Britt Wennerholm, Christina Bergh) indicate that while children conceived via ART have a slightly higher relative risk of preterm birth, low birth weight, and rare epigenetic imprinting disorders (such as Beckwith-Wiedemann and Angelman syndromes), absolute risks remain low. Ongoing prospective epigenetic studies indicate that parental subfertility itself—rather than laboratory micromanipulation—accounts for a substantial proportion of these observed variances. Empirical research also confirms that children and adolescents conceived via ART exhibit normal cognitive, neurodevelopmental, and psychosocial functioning compared to naturally conceived peers.
12. Cultural & Cross-Cultural Considerations
The global diffusion of assisted reproductive technology has intersected with diverse theological, legal, cultural, and socio-economic realities, creating varied regulatory landscapes and social reception. Cultural anthropologist Marcia Inhorn has extensively documented how kinship structures, patriarchy, and religious interpretations shape ART utilization in non-Western contexts. In many societies where childbearing is essential to social adulthood, feminine identity, and marital stability, involuntary childlessness carries severe social stigma, ostracization, and economic vulnerability, rendering ART an urgent social necessity rather than a lifestyle option.
Theological interpretations create divergent clinical boundaries across jurisdictions:
- Roman Catholicism: Official Vatican doctrine (promulgated in Donum Vitae and Dignitas Personae) strictly prohibits ART, asserting that procreation must remain inseparable from the unitive conjugal act and condemning the extracorporeal handling and destruction of human embryos.
- Sunni Islam: Authoritative religious rulings endorse IVF and ICSI provided that procedures utilize the gametes of legally married spouses during the active duration of the marriage; third-party gamete donation and gestational surrogacy are strictly prohibited, as they violate Islamic lineage and genealogical purity (nasab).
- Shia Islam: Distinct fatwas issued in countries like Iran permit donor gametes and gestational surrogacy under strict legal conditions, generating unique cross-border reproductive travel from neighboring nations.
- Judaism (Halakhic Law): Traditional Halakhic rulings largely support ART to fulfill the biblical commandment to “be fruitful and multiply,” with specialized rabbinical supervisors overseeing laboratory protocols to ensure chain of custody.
Global economic disparities have driven the expansion of cross-border reproductive care (reproductive tourism). Patients routinely travel to destinations with favorable legal frameworks, lower clinical costs, or available third-party donors, raising complex human rights concerns regarding the potential exploitation of socioeconomically vulnerable gestational carriers in the Global South.
13. Criticisms, Debates & Limitations
Assisted reproductive technology is surrounded by ongoing clinical, economic, and bioethical debate. Foremost among commercial criticisms is the commercialization and aggressive commodification of fertility care. The rapid influx of private equity investment into fertility clinics has raised concerns regarding the over-prescription of costly clinical “add-ons”—supplementary interventions such as time-lapse imaging, assisted hatching, physiological ICSI (PICSI), endometrial scratching, and routine PGT-A. Extensive systemic reviews by the Cochrane Collaboration and regulatory authorities like the UK Human Fertilisation and Embryology Authority (HFEA) emphasize that many add-ons lack robust RCT-based evidence showing improvements in cumulative live birth rates.
Bioethical debates center on the moral and legal status of the human preimplantation embryo. The production of surplus embryos during ART cycles has resulted in hundreds of thousands of cryopreserved embryos held in perpetual frozen storage worldwide. Couples and clinics face complex ethical decisions regarding their disposition: indefinite cryostorage, donation to other infertile couples, release for embryonic stem cell research, or compassionate thawing and disposal. Emerging technologies like CRISPR-Cas9 genome editing in human embryos, mitochondrial replacement therapy (so-called “three-parent IVF”), and non-medical sex selection intensify debates around modern eugenics, genetic enhancement, and the modification of the human germline.
Clinically, ART has notable physical and physiological limitations. It cannot overcome age-related oocyte biological senescence; women over the age of 42 using autologous oocytes experience low live birth rates due to pervasive meiotic aneuploidy. Furthermore, procedures carry inherent maternal medical risks, including ovarian hyperstimulation syndrome (OHSS), procedural bleeding, pelvic infection, and an increased incidence of placenta accreta spectrum disorders in pregnancies achieved through ART.
14. Related Terms & Distinctions
To preserve diagnostic and clinical precision, ART must be distinguished from related concepts across reproductive medicine:
- Assisted Reproductive Technology (ART) vs. Intrauterine Insemination (IUI): IUI entails the laboratory preparation and concentration of motile spermatozoa, which are introduced directly into the uterine cavity via a fine catheter around ovulation. Because gamete interaction occurs entirely in vivo within the female reproductive tract and no oocyte manipulation occurs outside the body, IUI is excluded from the technical definition of ART.
- In Vitro Fertilization (IVF) vs. Intracytoplasmic Sperm Injection (ICSI): While all ICSI procedures are ART cycles, ICSI differs from standard IVF in its fertilization mechanics. Conventional IVF relies on passive co-incubation where sperm naturally penetrate the oocyte; ICSI involves active physical injection of a single sperm directly into the oocyte cytoplasm, primarily indicated for severe male-factor infertility or unexplained prior IVF failure.
- Gamete Intrafallopian Transfer (GIFT) and Zygote Intrafallopian Transfer (ZIFT): Earlier historical iterations of ART. GIFT involved laparoscopically transferring unfertilized oocytes and sperm directly into the Fallopian tubes; ZIFT involved laboratory fertilization followed by laparoscopic transfer of the zygote into the tube. Both methods have been largely replaced by transcervical intrauterine blastocyst transfers.
- Infertility vs. Subfertility: Infertility is defined by the World Health Organization as a disease of the reproductive system characterized by the failure to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse. Subfertility is a descriptive state denoting reduced fecundity or a prolonged time to conception, but not necessarily an absolute inability to conceive.
- Elective Egg Freezing (Social Freezing) vs. Medical Oncofertility: Elective cryopreservation is undertaken by individuals seeking to mitigate natural age-related fertility decline, whereas medical oncofertility involves urgent gamete banking prior to immediate gonadotoxic treatments or surgical sterilizing procedures.
15. Summary / Key Takeaways
Assisted reproductive technology encompasses all biomedical interventions involving the extracorporeal handling of human oocytes, sperm, or embryos to establish pregnancy. Anchored by the foundational procedures of IVF and ICSI, ART has evolved from an experimental treatment for tubal factor infertility into an advanced clinical discipline integrating genomic medicine, ultra-rapid vitrification, and precision reproductive endocrinology. These interventions have facilitated the births of millions of individuals worldwide while expanding reproductive autonomy across diverse clinical indications and family structures.
Nevertheless, ART operates at the intersection of complex biological boundaries, cultural values, economic incentives, and bioethical concerns. Key challenges include the proliferation of unvalidated clinical add-ons, disparities in global financial access, the disposition of cryopreserved embryos, and emerging frontiers like germline editing and stem-cell-derived gametogenesis. Navigating this expanding landscape requires evidence-based clinical practices, transparent registry reporting, and thoughtful ethical oversight.
References
- American College of Obstetricians and Gynecologists. (2020). Preimplantation genetic testing: ACOG Committee Opinion, Number 799. Obstetrics & Gynecology, 135(3), e133–e137. https://pubmed.ncbi.nlm.nih.gov/32080053/
- Centers for Disease Control and Prevention. (2023). Assisted reproductive technology surveillance — United States, 2020. U.S. Department of Health and Human Services. https://www.cdc.gov/art/
- Edwards, R. G., Steptoe, P. C., & Purdy, J. M. (1980). Establishing full-term human pregnancies using cleaving embryos grown in vitro. British Journal of Obstetrics and Gynaecology, 87(9), 737–756. https://pubmed.ncbi.nlm.nih.gov/6774775/
- Inhorn, M. C., & Patrizio, P. (2015). Infertility around the globe: New thinking on gender, reproductive technologies and global movements in the 21st century. Human Reproduction Update, 21(4), 411–426. https://pubmed.ncbi.nlm.nih.gov/25801630/
- Palermo, G., Joris, H., Devroey, P., & Van Steirteghem, A. C. (1992). Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. The Lancet, 340(8810), 17–18. https://pubmed.ncbi.nlm.nih.gov/1351601/
- World Health Organization. (2020). International classification of diseases, 11th revision (ICD-11): Infertility and assisted reproduction definitions. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/infertility
- Zegers-Hochschild, F., Adamson, G. D., Dyer, S., Racowsky, C., de Mouzon, J., Sokol, R., Rienzi, L., Sunde, A., Schmidt, L., Cooke, I. D., Simpson, J. L., & van der Poel, S. (2017). The International Glossary on Infertility and Fertility Care, 2017. Fertility and Sterility, 108(3), 393–406. https://pubmed.ncbi.nlm.nih.gov/28760517/